The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
Most patients with multiple myeloma treated with current therapies, including immunomodulatory drugs, eventually develop relapsed/refractory disease. Clinical activity of lenalidomide relies on degradation of Ikaros and the consequent reduction in IRF4 expression, both required for myeloma cell surv...
Shranjeno v:
| Principais autores: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Ferrata Storti Foundation
2017-10-01
|
| Serija: | Haematologica |
| Online dostop: | https://haematologica.org/article/view/8226 |
| Oznake: |
Brez oznak, prvi označite!
|